

ORAL VERSUS VAGINAL
METRONIDAZOLE IN THE
TREATMENT OF SYMPTOMATIZING
BACTERIAL VAGINOSIS IN WOMEN
DURING CHILD BEARING PERIOD

Thesis

*Submitted for Partial Fulfillment of Master
Degree in Obstetrics & Gynecology*

By

(Marwa Hassan Loutfy El-Galil El-Daghashi)

M.B., B.Ch

Al-Azhar University – December 2003

Obstetrics and Gynecologic resident

Health Insurance Institute

Shoubra Hospital

Supervised by

Dr. Ahmed Mohamed Nour El-Din Hashaad

Professor of Obstetrics and Gynecology

Faculty of Medicine – Ain Shams University

Dr. Ahmed Adel Tharwat

Ass. Prof. Of Obstetrics and Gynecology

Faculty of Medicine – Ain Shams University

Faculty of Medicine

Ain Shams University

2014

Acknowledgement

First and foremost I thank ALLAH for helping me and directing me to every success I have reached and will be reached.

*I would like to express my endless gratitude and appreciation to **Prof. Dr. Ahmed Mohamed Nour El-Din Hashaad** Professor of Obstetrics & Gynecology Ain Shams University for giving me the honor of working under his supervision and providing me with a lot of encouragement and support.*

*I am also offering my deep gratitude and warm thanks to **Dr. Ahmed Adel Tharwat** Assistant Professor of Obstetrics & Gynecology Ain Shams University, for his kind supervision, generous advice, unlimited help and valuable guide. Definitely no words can express my obligations to him.*

I will never forget to thank all my patients, to whom this study was carried out. Without their cooperation this study would never go to appear.

Finally, no word can describe the support and endless encouragement offered by my family.

Marwa Hassan Loutfy

List of Contents

	Page
Acknowledgment	-
List of Abbreviations	I
List of Tables.....	III
List of Figures	V
Protocol of thesis.....	-
Review of Literature	1
Normal Vaginal Flora	1
Introduction on Bacterial Vaginosis	4
Risk Factors of Bacterial Vaginosis.....	8
Vaginal Flora and Microenviroment.....	10
Clinical Picture of Bacterial Vaginosis.....	14
Complicatins of Bacterial Vaginosis	17
Laboratory Diagnosis of Bacterial Vaginosis.....	22
Differential Diagnosis of Bacterial Vaginosis.....	30
Treatment of Bacterial Vaginosis	34
Metronidazole	62
Patients and Methods	69
Results	74
Discussion	89
Summary	96
Conclusion and Recommendations.....	102
References	103
Arabic Summary	--

List of Abbreviations

<i>A. vaginae</i>	<i>Atopobium vaginae</i>
AIDS	Acquired Immune Deficiency Syndrome
b.	Bacteroid
BV	Bacterial Vaginosis
<i>C. albicans</i>	<i>Candida albicans</i>
CDC	Center of disease control
CIN	Cervical intraepithelial neoplasia
<i>E. coli</i>	<i>Escherichia coli</i>
FAO	Food and Agriculture Organization of the United Nations
FDA	Foodand Drug Administration
<i>G. vaginalis</i>	<i>Gardnerella vaginalis</i>
GIT	Gastrointestinal Tract
H ₂ O ₂	Hydrogen peroxide
HDL	High Density Lipoproteins
HIV	Human Immune Deficiency Virus
HPF	High power field
IUD	Intra Uterine Device
KOH	Potassium hydroxide
<i>L.</i>	<i>Lactobacillus</i>
<i>M. curtisii</i>	<i>Mobiluncus curtisii</i>
<i>M. hominis</i>	<i>Mycoplasma hominis</i>
<i>M. Mulieri</i>	<i>Mobiluncus Mulieri</i>
mRNA	Messenger Ribonucleic acid
<i>P. bivia</i>	<i>Prevotella bivia</i>
PAP	Proline amino peptidase

List of Abbreviations_(Cont.)

Pap smear	Papanicolaou smear
PCR	Polymerase chain reaction
PID	Pelvic inflammatory disease
PROM	Premature rupture of the membranes
rDNA	Ribosomal Deoxyribonucleic acid
RVVC	Recurrent vulvovaginal candidiasis
spp.	Species
STD	Sexually transmitted disease
STI	Sexually transmitted infection
<i>T. vaginalis</i>	<i>Trichomonas vaginalis</i>
<i>U. urealyticum</i>	<i>Ureaplasma urealyticum</i>
US	United States
UTI	Urinary tract infection
VVC	Vulvo-vaginal candidiasis
WHO	World Health Organization
yrs.	Years

List of Tables

<i>Table</i>	<i>Title</i>	<i>Page</i>
1	Standardized scoring method for evaluation of Gram-stained smears for the diagnosis of BV	26
2	Comparison between ages in both groups	75
3	Comparison between parity in both groups before and after treatment	75
4	Comparison between parity in both groups after treatment	77
5	Comparison between contraception in both groups before and after treatment	79
6	Comparison between contraception in both groups after treatment	81
7	Comparison of vaginal discharge, KOH and clue cells within the two groups before and after treatment	82
8	Comparison of vaginal discharge, KOH, and clue cells between the two groups after treatment	83
9	Comparison of vaginal PH within the two groups before and after treatment using T test	84
10	Comparison of vaginal PH between the two groups after treatment using T test	85

List of Tables (Cont.)

<i>Table</i>	<i>Title</i>	<i>Page</i>
11	Comparison of vaginal PH within the two groups before and after treatment using χ^2 test	86
12	Comparison of vaginal PH between the two groups after treatment using χ^2 test	87
13	Comparison of cure rate between the two groups after 4 weeks using χ^2 test	88
14	Comparison of recurrence rate between the two groups after 4 weeks using χ^2 test	89

List of Figures

Fig.	Title	Page
1	Gram stain of normal vaginal contents	11
2	Clue cells in saline	15
3	Different vaginal morphotypes	26
4	PH scale graded strip	73
5	Comparison between parity in group A (oral) before and after treatment.	75
6	Comparison between parity in group B (vaginal) before and after treatment.	75
7	Comparison between parity in both groups after treatment.	77
8	Comparison between contraception in group A before and after treatment.	79
9	Comparison between contraception in group B before and after treatment	79
10	Comparison between contraception in both groups after treatment.	80
11	Comparison of vaginal discharge, KOH and clue cells in group A before and after treatment	81
12	Comparison of vaginal discharge, KOH and clue cells in group B before and after treatment	81

List of Figures(Cont.)

Fig.	Title	Page
13	Comparison of vaginal discharge, KOH, and clue cells between the two groups after treatment	82
14	Comparison of vaginal PH within the two groups before and after treatment using T test	83
15	Comparison of vaginal PH between the two groups after treatment using T test	84
16	Comparison of vaginal PH within the two groups before and after treatment using χ^2 test	85
17	Comparison of vaginal PH between the two groups after treatment using χ^2 test	86
18	Comparison of cure rate between the two groups after 4weeks	87
19	Comparison of recurrence rate between the two groups after 4weeks	88

ORAL VERSUS VAGINAL
METRONIDAZOLE IN THE
TREATMENT OF SYMPTOMATIZING
BACTERIAL VAGINOSIS IN WOMEN
DURING CHILD BEARING PERIOD

Protocol of Thesis

*Submitted for Partial Fulfillment of Master
Degree in Obstetrics & Gynecology*

By

Marwa Hassan Loutfy El-Galil El-Daghashi

M.B., B.Ch

Al-Azhar University – December 2003

Supervised by

Prof. Dr. Ahmed Mohamed Nour El-Din Hashaad

Professor of Obstetrics and Gynecology
Faculty of Medicine – Ain Shams University

Dr. Ahmed Adel Tharwat

Lecturer of Obstetrics and Gynecology
Faculty of Medicine – Ain Shams University

**Faculty of Medicine
Ain Shams University
2009**

Introduction

Bacterial vaginosis is considered the most common cause of vaginal infections in women of reproductive age world wide. The defining characteristic of bacterial vaginosis is the replacement of normal vaginal lactobacillus bacterial flora with facultative anaerobes (*Gardnerella vaginalis* and *Mycoplasma hominis*) and/or anaerobes (*Prevotella*, *Peptostreptococcus*, *Eubacterium*, and *Mobiluncus*) with an increase in vaginal PH from less than 4.5 to as high as 7.0. In such condition the concentrations of bacteria increase from 100-fold to 1000-fold (*French et al., 1997*).

At least 50% of women with bacterial vaginosis are completely asymptomatic.

The current standard for clinical diagnosis of vaginal infections requires the presence of 3 of 4 Amsel's criteria.

- 1- Thin, white, homogeneous discharge.
- 2- Clue cells on microscopy of wet mount.
- 3- PH of vaginal fluid >4.5.
- 4- Release of a fishy odour on adding alkali (10% KOH)

(ACOG Practice, 2006)

It is more common in black race, smoking, routine vaginal douching, recent use of broad spectrum antibiotic and in those with IUDs (*Workowski et al., 2006*).

While bacterial vaginosis is not regarded a sexually transmitted diseases, the prevalence is generally higher among sexually active than sexually non active women (*Yens et al., 2006*). It is high among women with pelvic inflammatory disease (PID) more or less being predictive of subsequent PID associated with gonorrhoea or Chlamydia, it has been associated with an increase incidence of vaginal cuff cellulitis and abscess formation following trans-vaginal hysterectomy (*Ness et al., 2005*).

But, in pregnancy bacterial vaginosis is associated with late miscarriage, preterm birth, preterm premature rupture of membranes, and postpartum endometritis (*Hauth Jr et al., 2000*).

The goal of bacterial vaginosis treatment is to promote a predominance of lactobacilli in women's vaginal flora and to decrease anaerobic and other bacteria (*Nyirjesy, 2006*). Bacterial vaginosis can be treated with antibiotics such as metronidazole and clindamycin. However, there is a considerable rate of recurrence (*Bradshaw et al., 2006*).

Oral or vaginal metronidazole for 7 days is the first-choice medication for treating bacterial vaginosis (*Kou Mans et al., 2002*).

Although oral therapy is less messy and inexpensive than vaginal therapy, can be taken any where, and has no local side effects. It has a metallic taste and some G.I.T. troubles (nausea, vomiting and diarrhea), that may affect patient compliance rendering course complete of treatment is in doubt which may result in recurrence. On the other hand, vaginal routes are less likely than the oral forms to cause systemic side effects mainly G.I.T. troubles which are one of the causes for patient non compliance. There are many researches that compare oral versus vaginal therapy with metronidazole. The choice of the route of metronidazole administration depends mainly on many factors such as efficacy, cost, convenience, compliance and patient preference (*Nyirjesy et al., 2006*).

Aim of the Work

To compare oral versus vaginal metronidazole in the treatment of symptomizing bacterial vaginosis among women in child bearing period.

Patients and Methods

This is an interventional study that will be carried out at Ain Shams University Maternity Hospital in out-patient gynecological clinic. The study will include (50) females in child bearing period with bacterial vaginosis as diagnosed by Amsel's criteria.

An explanation of the study will be informed to the participants and an informed consent will be taken from them.

A detailed medical history of all patients will be recorded. Complete general and vaginal examination will be performed.

Exclusion Criteria:

- 1- Pregnant females.
- 2- Postmenopausal females.
- 3- Females with another vaginal infections.

The patients will be subdivided into tow groups:

-The first group will receive oral metronidazole, 500mg twice daily for 7 days.

-While the second group will receive intravaginal metronidazole gel 0.75% or vaginal suppositories 5gm once daily for 5 days.